Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
Colorectal Cancer
About this trial
This is an interventional treatment trial for Colorectal Cancer
Eligibility Criteria
Inclusion Criteria: Histological diagnosis of colorectral adenocarcinoma. Measurable or assessable lesions. Age: 15 ~ 75 years. Performance Status (ECOG): 0 ~ 2. Prior chemotherapy within 2 regimens. Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC 3,500/mm3. Hb 10.0 g/dl. Platelet count 100,000/mm3. GOT and GPT 2.5times the upper limit of normal (excluding liver metastasis). T-Bil 3.0mg/dl. Creatinine within the upper limit of normal. Normal ECG (not considering clinically unimportant arrhythmias and ischemic changes). (10) Predicted survival for >8 weeks. (11) Able to give written informed consent. Exclusion Criteria: Severe pleural effusion or ascites. Metastasis to the central nervous system (CNS). Active gastrointestinal bleeding. Active infection. Uncontrolled ischemic heart disease. Serious complications (such as intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure, or hepatic failure). Active multiple cancer. Severe mental disorder. Pregnancy, possible pregnancy, or breast-feeding. Patients with neuropathy ≥ grade 2 Judged to be ineligible for this protocol by the attending physician.
Sites / Locations
- Hokkaido University Hospital (Hokkaido University Graduate School of Medicine)